Skip to content
InMed-logo-01
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
  • Pharmaceutical
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Cannabinoid Analogs
    • Cannabinoids in Development
  • Products
    • Cannabidivarin (CBDV)
    • Tetrahydrocannabivarin (THCV)
    • Cannabichromene (CBC)
    • Cannabicitran (CBT)
  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
Menu
  • Manufacturing
    • Cannabinoid Manufacturing Expertise
    • IntegraSyn™ Cannabinoid Manufacturing
    • BayMedica Cannabinoid Biosynthesis
  • Pharmaceutical
    • INM-755 for Epidermolysis Bullosa
    • INM-088 for Glaucoma
    • Novel Cannabinoid Analogs
    • Cannabinoids in Development
  • Products
    • Cannabidivarin (CBDV)
    • Tetrahydrocannabivarin (THCV)
    • Cannabichromene (CBC)
    • Cannabicitran (CBT)
  • Investor
    • News Releases
    • Events
    • Stock Information
    • Corporate Governance
    • Financials & AGM
    • Filings
    • Presentations
    • Media
  • About
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partners and Collaborators
    • Events Calendar
    • Careers
    • Contact
  • Learn
    • What is Cannabinol (CBN)?
    • What is Epidermolysis Bullosa (EB)?
    • What is Glaucoma?
    • Cannabinoid Manufacturing Economics 101
    • GMP Manufacturing Standards by Product Type
    • Cannabis Treatments for Glaucoma
    • Cannabinoid Science
    • Articles and Videos
NASDAQ_Logo
InMed Launches Sales of Tetrahydrocannabivarin (THCV)
B2B sales of d9-THCV to wholesalers, suppliers and end-product manufacturers in the health and wellness sector
learn about THCV
InMed Commences Sales of Cannabidivarin (CBDV)
B2B sales to wholesalers, suppliers and end-product manufacturers in the health and wellness sector
learn about CBDV
Rare Cannabinoid Experts
We manufacture, clinically develop and commercialize minor cannabinoids.
Cannabinoid Expertise
Bringing you pure, high-quality synthesized rare cannabinoids
Wholesale supplier of rare cannabinoids CBC and CBT. CBDV and THCV coming soon.
Learn More
Unlocking the therapeutic potential of rare cannabinoids
Phase 2 clinical program in epidermolysis bullosa.
Learn More
Developing new patentable cannabinoids for pharmaceutical development
A library of cannabinoid analogs that can be selectively modified
Cannabinoid Library

Unparalleled rare cannabinoid expertise

InMed is a leader in the manufacturing, development and commercialization of rare cannabinoids. Our manufacturing technologies produce several rare cannabinoids for pharmaceutical development and consumer products.

Cannabinoid Manufacturing Expertise

A Portfolio of Rare Cannabinoids for the Health and Wellness Sector

InMed’s subsidiary, BayMedica, is producing a portfolio of premium rare cannabinoids as raw ingredients for your health and wellness products. We have engineered bioidentical cannabinoids with high purity and consistency, and free of THC. We currently manufacture the rare, minor cannabinoids tetrahydrocannabivarin (d9-THCV) cannabidivarin (CBDV), cannabichromene (CBC) and cannabicitran (CBT) which are available for B2B purchase.

Learn about our Products

Unlocking the Therapeutic Potential of Rare Cannabinoids

Rare cannabinoids are an emerging class of compounds which are gaining interest for their potential medical benefits. InMed has initiated two pharmaceutical programs – a Phase 2 clinical trial for epidermolysis bullosa, a rare genetic skin disease, and has begun preparing to initiate clinical studies in glaucoma following promising preclinical results.

Learn About our Pharmaceutical Programs

Producing rare cannabinoids for a variety of uses

InMed’s rare cannabinoids are being applied across a spectrum of uses – from pharmaceutical development to wholesale sales to the consumer health and wellness sector. Our pharmaceutical programs include a Phase 2 clinical program in dermatology and a preclinical program in glaucoma. Our division, BayMedica, is the leading large batch producer of wholesale CBC (cannabichromene) cannabinoid for the consumer health and wellness industry. In addition to CBC, we have initiated sales of tetrahydrocannabivarin (d9-THCV), cannabidivarin (CBDV) and cannabicitran (CBT). Our portfolio also includes a growing library of patentable rare cannabinoid analogs for development.

learn about our rare cannabinoid programs

Experienced team with a successful track record

Together, InMed and BayMedica bring extensive know-how in cannabinoid science, manufacturing and development. We’ve combined our complementary expertise to become a leading manufacturer and developer of high-quality rare cannabinoids.

Meet the team

Latest News

InMed Pharmaceuticals Submits Clinical Trial Applications to Evaluate INM-755 (Cannabinol) Cream in a Phase 2 Trial for Epidermolysis Bullosa

April 28, 2021
Learn More

InMed Pharmaceuticals Announces Voluntary Delisting from TSX

April 27, 2021
Learn More

InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn™

April 26, 2021
Learn More

InMed to Present at Virtual Conferences in March 2021

March 3, 2021
Learn More

InMed Announces Closing of US$4.5 Million Private Placement

February 16, 2021
Learn More

InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results

February 11, 2021
Learn More

InMed Announces Publication of Peer-Reviewed Study Highlighting Potential Role of Rare Cannabinoids THCV, CBC and others on Skin Conditions

Jun 14, 2022
Learn More

InMed Launches THCV, Expanding its Portfolio of Rare Cannabinoids for the Health and Wellness Sector

Jun 09, 2022
Learn More

InMed Pharmaceuticals Announces Closing of $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

Jun 06, 2022
Learn More

InMed Pharmaceuticals Announces $5 Million Registered Direct and Private Placement Offerings Priced At-The-Market Under Nasdaq Rules

Jun 02, 2022
Learn More

InMed Pharmaceuticals Reports Third Quarter Fiscal 2022 Financial Results and Provides Business Update

May 13, 2022
Learn More

InMed to Supply Rare Cannabinoids to Radicle Science’s “Radicle Energy Study” to Assess the Health Effects of THCV

May 05, 2022
Learn More
See all news

Investor Alerts

Sign up to receive news releases from InMed Pharmaceuticals.
SIGN UP


INM-755

A cannabinol (CBN) topical cream in Phase 2 clinical trials for epidermolysis bullosa
Learn More

THCV Tetrahydrocanabivarin

InMed's subsidiary BayMedica has begun B2B sales of d9-THCV for the health and wellness industry
Learn More

Novel Cannabinoid Analogs

Our patentable cannabinoid analogs can be slightly modified to target specific pharmacological properties.
Learn More
InMed-logo-mono
#310 – 815 West Hastings St.
Vancouver, BC, Canada
V6C 1B4

Manufacturing

  • Cannabinoid Manufacturing Expertise
  • IntegraSyn™ Cannabinoid Manufacturing
  • BayMedica Cannabinoid Biosynthesis

Pharmaceutical

  • INM-755 for Epidermolysis Bullosa
  • INM-088 for Glaucoma
  • Novel Cannabinoid Analogs
  • Cannabinoids in Development

Investor

  • News
  • Events
  • Stock Information
  • Corporate Governance
  • Financials & AGM
  • Filings
  • Presentations
  • Media

Products

  • Cannabidivarin (CBDV)
  • Tetrahydrocannabivarin (THCV)
  • Cannabichromene (CBC)
  • Cannabicitran (CBT)

About

  • Management
  • Board of Directors
  • Scientific Advisory Board
  • Partners and Collaborators
  • Events Calendar
  • Careers
  • Contact

Learn

  • What is Cannabinol (CBN)?
  • What is Epidermolysis Bullosa (EB)?
  • What is Glaucoma?
  • Cannabinoid Manufacturing Economics 101
  • GMP Manufacturing Standards by Product Type
  • Cannabinoids for Glaucoma
  • Cannabinoid Science
  • Articles and Videos

© Copyright 2022 InMed Pharmaceuticals Inc.

  • Privacy Policy
  • Terms of Use
  • Legal Disclaimer
  • Find Us On:
Subscribe

Sign up to receive emails from InMed Pharmaceuticals

Name*
Consent